Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 2/20 | 0.35 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.33 |
| ▸ | DRD2 | P14416 | 2/20 | 0.33 |
| ▸ | DRD3 | P35462 | 2/20 | 0.33 |
| ▸ | DRD1 | P21728 | 1/20 | 0.33 |
| ▸ | DRD4 | P21917 | 1/20 | 0.33 |
| ▸ | DRD5 | P21918 | 1/20 | 0.33 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | CA9 | Q16790 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | HTR1D | P28221 | 1/20 | 0.31 |
| ▸ | CNR2 | P34972 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1121144 | 0.78 | MAPT (0.39) | KDM4CCYP3A4ALDH1A1LMNA | |
| SCHEMBL15024162 | 0.74 | MAPK1 (0.37) | KDM4CCYP3A4PDE10AALDH1A1 | |
| SCHEMBL7139493 | 0.71 | DRD2 (0.51) | DRD2DRD3DRD1DRD4DRD5 | |
| SCHEMBL4503960 | 0.68 | LMNA (0.42) | DRD2DRD3DRD1DRD4DRD5 | |
| SCHEMBL576035 | 0.66 | CA2 (0.50) | DRD2DRD3DRD1DRD4DRD5 | |
| SCHEMBL25383081 | 0.65 | DRD2 (0.38) | DRD2DRD3DRD1DRD4DRD5 | |
| SCHEMBL408478 | 0.64 | CA1 (0.68) | CA1CA2CA9ALDH1A1 | |
| SCHEMBL31306825 | 0.63 | CA1 (0.66) | CA1CA2CA9ALDH1A1 | |
| SCHEMBL22444698 | 0.62 | DRD2 (0.57) | DRD2DRD3DRD1DRD4DRD5 | |
| SCHEMBL8821206 | 0.62 | CA1 (0.56) | CA1CA2CA9LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9162988-B2 | Therapeutic or prophylactic agent for allergic dermatitis | TORAY INDUSTRIES, INC. (JP) | 2015-10-20 | — | — | US | disclosed |
| US-9162988-B2 | Therapeutic or prophylactic agent for allergic dermatitis | TORAY INDUSTRIES, INC. (JP) | 2015-10-20 | — | — | US | disclosed |
| US-20130150390-A1 | THERAPEUTIC OR PROPHYLACTIC AGENT FOR ALLERGIC DERMATITIS | TORAY INDUSTRIES, INC. (JP) | 2013-06-13 | — | — | US | disclosed |
| US-20130150390-A1 | THERAPEUTIC OR PROPHYLACTIC AGENT FOR ALLERGIC DERMATITIS | TORAY INDUSTRIES, INC. (JP) | 2013-06-13 | — | — | US | disclosed |
| EP-1840121-B1 | GLYCINE DERIVATIVE AND USE THEREOF | TORAY INDUSTRIES (JP) | 2012-08-29 | — | — | EP | disclosed |
| EP-2039687-B1 | THERAPEUTIC OR PROPHYLACTIC AGENT FOR MULTIPLE SCLEROSIS | TORAY INDUSTRIES (JP) | 2012-05-02 | — | — | EP | disclosed |
| EP-2042171-B1 | THERAPEUTIC OR PROPHYLACTIC AGENT FOR ALLERGIC DERMATITIS | TORAY INDUSTRIES (JP) | 2011-05-11 | — | — | EP | disclosed |
| US-7893046-B2 | agent comprises as an effective ingredient a glycine derivative or a pharmaceutically acceptable salt thereof, for example [(E)-2-(2,6-dichlorobenzamido)-5-[4-(isopropyl-pyrimidin-2-ylamino)phenyl]pent-4-enoic acid] | TORAY INDUSTRIES, INC. (JP) | 2011-02-22 | — | — | US | disclosed |
| US-7893046-B2 | agent comprises as an effective ingredient a glycine derivative or a pharmaceutically acceptable salt thereof, for example [(E)-2-(2,6-dichlorobenzamido)-5-[4-(isopropyl-pyrimidin-2-ylamino)phenyl]pent-4-enoic acid] | TORAY INDUSTRIES, INC. (JP) | 2011-02-22 | — | — | US | disclosed |
| US-7893046-B2 | agent comprises as an effective ingredient a glycine derivative or a pharmaceutically acceptable salt thereof, for example [(E)-2-(2,6-dichlorobenzamido)-5-[4-(isopropyl-pyrimidin-2-ylamino)phenyl]pent-4-enoic acid] | TORAY INDUSTRIES, INC. (JP) | 2011-02-22 | — | — | US | disclosed |
| US-20090093508-A1 | THERAPEUTIC OR PROPHYLACTIC AGENT FOR ALLERGIC DERMATITIS | TORAY INDUSTRIES, INC. (JP) | 2009-04-09 | — | — | US | disclosed |
| US-20090093508-A1 | THERAPEUTIC OR PROPHYLACTIC AGENT FOR ALLERGIC DERMATITIS | TORAY INDUSTRIES, INC. (JP) | 2009-04-09 | — | — | US | disclosed |
| US-20090093508-A1 | THERAPEUTIC OR PROPHYLACTIC AGENT FOR ALLERGIC DERMATITIS | TORAY INDUSTRIES, INC. (JP) | 2009-04-09 | — | — | US | disclosed |
| EP-2042171-A1 | THERAPEUTIC OR PROPHYLACTIC AGENT FOR ALLERGIC DERMATITIS | Toray Industries, Inc. (JP) | 2009-04-01 | — | — | EP | disclosed |
| EP-2039687-A1 | THERAPEUTIC OR PROPHYLACTIC AGENT FOR MULTIPLE SCLEROSIS | Toray Industries, Inc. (JP) | 2009-03-25 | — | — | EP | disclosed |
| EP-2033637-A1 | THERAPEUTIC OR PROPHYLACTIC AGENT FOR LEUKEMIA | Toray Industries, Inc. (JP) | 2009-03-11 | — | — | EP | disclosed |
| US-20080085910-A1 | Glycine Derivative and Use Thereof | TORAY INDUSTRIES, INC. (JP) | 2008-04-10 | — | — | US | disclosed |
| US-20080085910-A1 | Glycine Derivative and Use Thereof | TORAY INDUSTRIES, INC. (JP) | 2008-04-10 | — | — | US | disclosed |
| US-20080085910-A1 | Glycine Derivative and Use Thereof | TORAY INDUSTRIES, INC. (JP) | 2008-04-10 | — | — | US | disclosed |
| EP-1840121-A1 | GLYCINE DERIVATIVE AND USE THEREOF | TORAY INDUSTRIES, INC. (JP) | 2007-10-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090093508-A1 | THERAPEUTIC OR PROPHYLACTIC AGENT FOR ALLERGIC DERMATITIS | HRH2, TSLP, ENPEP | SCN9A 2692/4885KDM4C 3223/4885CYP3A4 4581/4885 |
| US-20130150390-A1 | THERAPEUTIC OR PROPHYLACTIC AGENT FOR ALLERGIC DERMATITIS | HRH2, TSLP, ENPEP | SCN9A 2692/4885KDM4C 3223/4885CYP3A4 4581/4885 |
| US-20080085910-A1 | Glycine Derivative and Use Thereof | GNMT, SI, SLC7A11 | SCN9A 2028/4885KDM4C 3365/4885CYP3A4 339/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.